degree of variabilities in overall survival (OS) and responses to treatment with individual drugs or their combinations. Moreover, the biological mechanisms underlying these clinical differences hindering the development of personalized care are inadequately understood.
To facilitate treatment decisions and improve our understanding of tumor biology, a simple and reliable molecular classification system is needed. Several such systems have been proposed on the basis of gene expression profiling (GEP). Bergsagel et al. 3 identified eight MM subtypes with distinct cyclin D expression and translocation patterns.
Using unbiased hypothesis-free transcriptome analysis, Zhan et al. and
Broyl et al. identified 7-10 molecular subtypes of MM. 4, 5 This enabled the division of MM into high-risk or low-risk groups in studies with patients receiving total therapy 2 (TT2) 5 or TT3. 6 Moreover, GEP signatures correlated with the prognosis of MM have been described (for example UAMS-70 and the related UAMS-17, UAMS-80, IFM-15,
Millennium-100 and EMC-92). [6] [7] [8] [9] [10] Further, gene proliferation index (GPI-50), MRC-IX-6, and centrosome amplification index were found to be prognostic for MM patients. [11] [12] [13] Recently, Palumbo et al. proposed a revised international staging system (R-ISS) based on the serum b2-microglobulin level, the serum lactate dehydrogenase (LDH) level, and high-risk chromosome abnormalities [including del(17p), t(4;14), and t (14;16) translocations], which also provides prognostic information.
14 These studies were important steps forward in establishing an objective molecular classification for MM. However, three issues remain unaddressed: (1) the capacity to predict the treatment response, 15, 16 (2) the correlation between subtypes and specific pathways of plasma cell development, 17 and (3) the relatedness of classifiers to MM pathogenesis.
To address these questions, we explored whether gene coexpression modules around key signaling pathways conserved between germinal centre (GC) formation and MM pathogenesis might enable the molecular classification of MM. We were specifically interested in the dysregulation of gene networks controlling B cell differentiation to plasma cells in GC because these may play a crucial role in MM initiation. 18 Here we describe the identification of genes consistently coexpressed with Myeloid cell leukemia 1 (MCL1-module, MCL1-M) in MM, and their application in classifying MM into two major subtypes that are characterized by differences in prognosis, response to bortezomibbased treatment, and correlation to plasma cell development. These findings pave the way for establishing personalized care and improving our understanding of the etiology of MM. MCL1 is essential for germinal center formation and memory B cell generation, 26 and is indispensable for the maintenance of long-lived plasma cells in the BM. 27 Frequent gain of the chromosomal region 1q21, where MCL1 is located, was reported to be associated with MM progression and short survival of the patients. 28 Of the 87 known genes in MCL1-M, 63 are located on 1q (Supporting Information Figure   S1 and Table S2 ); a gene dosage-dependent expression was found for 39 of these 63 in MM with "MCL1-M high" signature (Supporting Information Figure S2 and Table S6 ). Comparison with the prognostic MM clusters defined by Zhan et al. 5 showed that the good prognostic CD-1, CD-2, and HY clusters predominantly contained MCL1-M low MM, and most of the MM in the poor prognostic PR, MS, and MF clusters showed the MCL1-M high signature (Supporting Information Table S7 ). However, most good prognostic LB MM showed the MCL1-M high signature. In GSE19784, the LB cluster was not confirmed. 4 The assignments of the same MM samples into the 10 clusters reported in GSE19784 4 did not correlate with the MCL1-M clustering (Supporting Information Table S8 ). Unlike the distinct response to VAD/PAD treatment arms between patients with MCL1-M high or MCL1-M low MM, nine of the ten previously defined clusters (except the MF cluster) 4 did not show distinct response to treatment regimens with or without bortezomib (Supporting Information Figure S5 ).
| M A TE RI A L S A ND M E TH ODS
The prognostic impact of MCL1 expression has been controversial. 39, 40 On the basis of the results shown in Figure 1 , we used univariate Cox regression analysis to assess the prognostic effect of all MCL1-M members. In both GSE2658 and GSE19784 data sets, MCL1 expression alone was not prognostic, but the other 15 MCL1-M members, including key regulators of osteoclast formation (ANXA2 41 ), chromatin structure (ANP32E 42 and H3F3A 43 ) and oncogenic transformation (TPM3 44 ) were strongly prognostic (Supporting Information Table S9 ). Table S5 ). Conversely, 68% of the MCL1-M low MM and 38% of the MCL1-M high MM harbored trisomies of chromosome 9, 11 and 15 (P 5 0.0002, Chi-square test, Supporting Information Table S5 ).
We further analyzed myeloma-characteristic SCNAs in MCL1-M signature-defined MM subtypes using the GSE29023 (n 5 115) and GSE26863 (n 5 180) array CGH data. In both data sets, 18% of the MCL1-M low subtype harbored 1q gain; but up to 77% of the Table   S12 ). These findings together demonstrate 1q gain as the most recurrent somatic genomic alterations in MCL1-M high MM.
| 1q gain as an early and clonal event during MM development
Previous reports of FISH analysis in unrelated patients have suggested 1q gain as a marker of MM progression. 28, 52 To infer the temporal order of 1q gain and other characteristic MM genomic abnormalities, we employed BubbleTree 53 to perform clonality analysis with the whole exome sequencing data for 112 MM samples reported by Lohr et al. 22 Among them, we identified thirty-nine samples harboring 1q gain, with 12 of them harboring high gain of 1q, for the clonality analysis (Supporting Information Table S13 ).
The number of clones with the SCNAs identified above ranged from 1 to 4; 18 MM samples harbored only one clone. Most of the major SCNAs appeared to be highly clonal. Thirteen, seven, and one MM samples harbored two, three and four clones, respectively; most SCNAs in samples with two multi-clones were clonal. 1q gain was clonal in 36 of the 39 MM samples analyzed. In three samples with subclonal 1q gain, the ploidy for 1q was 4 or 5 (Supporting Information   Table S13 ). These samples might have initially gained one (clonal) 1q segment and subsequently gained additional (subclonal) 1q segments (Supporting Information Figure S9 and Table S14 ). A representative sample (MMRC0571) with clonal 1q gain is shown in Figure 4 . Three clones were identified. The triploid heterozygous 1q gain belonged to We further assessed the cancer cell fraction (CCF) containing the driver mutations in MM harboring the 1q gain. Only a fraction of MM samples with 1q gain harbored these mutations, and they were either clonal or subclonal (Figure 4 and Supporting Information Figure S10 ). 
